Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 11 of 11 for “"chronic myelogenous leukemia"”.

  1. Proteogenomic Insights Into The Nature Of Chemoresistance In Chronic Myelogenous Leukemia

    Chronic Myelogenous Leukemia (CML) is a hematopoietic cancer caused by the formation of the Philadelphia chromosome, a reciprocal translocation of the ABL1 oncogene on chromosome 9, and the breakpoint cluster region gene (BCR) chromosome 22, resulting in the BCR-ABL oncoprotein. BCR-ABL is a …

    purdue-thes Repository record for Proteogenomic Insights Into The Nature Of Chemoresistance In Chronic Myelogenous Leukemia (opens in a new tab)

  2. Development of an RNA aptamer to PD173955N through SELEX

    … treat cancer patients.;The molecular basis for leukemia cancers are understood to a level where we are able to design treatments that specifically target proteins responsible for the disease. One of those proteins is the Bcr-Abl tyrosine kinase which is mostly responsible for chronic myelogenous

    iastate Repository record for Development of an RNA aptamer to PD173955N through SELEX (opens in a new tab)

  3. Investigating Novel Targets to Inhibit Cancer Cell Survival

    … survival of glioblastoma (GBM) or autophagy in chronic myelogenous leukemia (CML) cancer cells. One screen identified Phosphatidylinositol-4,5-bisophosphate 3-kinase catalytic subunit beta (PIK3CB) in the family of Phosphatidylinositol 3-kinases (PI3K) as a survival kinase gene in GBM. Work …

    vt Repository record for Investigating Novel Targets to Inhibit Cancer Cell Survival (opens in a new tab)

  4. NK Cell Function and Tumor Resistance in Mice Transgenic for Antibody to NK Inhibitory Receptors

    … antibody (5E6), allow NK cells to kill syngeneic leukemia cells more efficiently providing an enhanced anti-tumor effect. To study further the effect of Ly49C/I receptor blockade and improve tumor rejection, we developed a transgenic model whereby the 5E6 Fab antibody fragments are constitutively …

    utswmed Repository record for NK Cell Function and Tumor Resistance in Mice Transgenic for Antibody to NK Inhibitory Receptors (opens in a new tab)

  5. Identification of a Minimal Cis-element and Cognate Trans-factors Required for the Regulation of Rac2 Gene Expression during K562 Cell Differentiation

    … megakaryocytic differentiation of the human chronic myelogenous leukemia cell line K562 as the model system. Phorbol 12-myristate 13-acetate (PMA) stimulation of K562 cells resulted in increased Rac2 mRNA expression as analyzed by real time-polymerase chain reaction (RT-PCR). Luciferase …

    iupui Repository record for Identification of a Minimal Cis-element and Cognate Trans-factors Required for the Regulation of Rac2 Gene Expression during K562 Cell Differentiation (opens in a new tab)

  6. Evolution of protein structure function

    … selectivity for a particular kinase involved in Chronic myelogenous leukemia. We investigated this question by simulating two modern kinases, a strong (Abl) and a weak (Src) binder, with five of their common ancestors to regenerate the evolutionary pathway between them. In the second effort to …

    uiuc Repository record for Evolution of protein structure function (opens in a new tab)

  7. C-Rel Is A Transcriptional Target of Mesoderm Inducer In Xenopus Like 1 (Mixl1)

    … Aberrant MIXL1 expression is seen in human CML ( Chronic Myelogenous Leukemia) in blast crisis, AML (Acute myelogenous leukemia), B cell lymphomas and pediatric ALL (Acute lymphocytic leukemia). (ii) Retroviral transduction of Mixl1 induces AML in murine models. Nonetheless, mechanisms underlying …

    uthsc Repository record for C-Rel Is A Transcriptional Target of Mesoderm Inducer In Xenopus Like 1 (Mixl1) (opens in a new tab)

  8. Discovery of Dihydroartemisinin and Dasatinib Drug Combination to Cure Pooroutcome BCR-ABL+ Acute Lymphoblastic Leukemia

    … chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) and chronic myelogenous leukemia (CML). Food and Drug Administration (FDA)- approved BCR-ABL-specific kinase inhibitors (BCR-ABL–KIs) imatinib, dasatinib and nilotinib induce prolonged remissions in CML but poor leukemia-reduction …

    tenn-hsc Repository record for Discovery of Dihydroartemisinin and Dasatinib Drug Combination to Cure Pooroutcome BCR-ABL+ Acute Lymphoblastic Leukemia (opens in a new tab)

  9. Novel peptide-based approaches to study the activity and substrate specificity of protein kinases

    … the activity of endogenous SFKs expressed in chronic myelogenous leukemia (CML) cell lines and human platelets. In an attempt to develop a kinase assay more suitable for high-throughput screening applications, a number of new assay designs based on the use of luminescent lanthanide complexes …

    melbourne Repository record for Novel peptide-based approaches to study the activity and substrate specificity of protein kinases (opens in a new tab)

  10. Pax5 Haploinsufficiency Cooperates with BCR-ABL1 to Induce Acute Lymphoblastic Leukemia

    <p>Acute lymphoblastic leukemia (ALL) is the commonest pediatric malignancy and comprises several distinct subtypes each with its own unique pathogenesis, clinical behavior, and response to therapy. Chromosomal aberrations are a hallmark of ALL but alone fail to induce leukemia. Pediatric ALLs can …

    tenn-hsc Repository record for Pax5 Haploinsufficiency Cooperates with BCR-ABL1 to Induce Acute Lymphoblastic Leukemia (opens in a new tab)